Stanabol 50 Inj

British Dragon
💉
Stanabol 50 Inj British Dragon
Stanozolol · 50 mg/ml · 10 ml vial · 500 mg total
🧬
Category
Injectable DHT anabolic steroid
Aqueous suspension · no aromatization
💉
Form / Strength
50 mg/ml · 10 ml vial
500 mg per vial
🎯
Context
Lean mass · cutting · vascularity
Strength + SHBG reduction
⚙️
Administration
Intramuscular injection
Less oral liver burden · IM or deep SC

Typical Dose
50 mg/day
Or 50 mg EOD
Frequency
Daily or EOD
Short ester — frequent dosing
Duration
6–8 weeks
1 vial = 10-day supply at 50 mg/day
Lab Tested
Manufacturer British Dragon
Brand Winstrol Depot
Substance Stanozolol
Concentration 50 mg/ml
Pack Size 10 ml
Out of Stock

Overview

Stanabol 50 Inj British Dragon is an aqueous suspension of stanozolol at 50 mg/ml, supplied in a 10 ml vial — 500 mg of stanozolol per vial. Injectable stanozolol contains the same 17α-alkylated compound as the oral tablets but bypasses gastrointestinal absorption and first-pass hepatic metabolism, resulting in more consistent bioavailability and moderately reduced — though not eliminated — hepatic stress relative to the oral forms. At steroidwarehouse.com the complete British Dragon stanozolol range includes Stanabol Tablets 10 mg, Stanabol 50 Tablets, and Stanabol 50 Inj.

Stanozolol · 50 mg/ml 10 ml vial · 500 mg total Aqueous suspension · IM injection No aromatization SHBG reduction 17α-AA — still hepatotoxic injectable Max 8 weeks

About the Compound

Active substance
Stanozolol
Class
DHT-derived anabolic steroid
Anabolic / Androgenic ratio
320 / 30
Form
Aqueous suspension · IM injection
Aromatization
None
SHBG binding
Strong — major free-T amplifier
Vial content
10 ml × 50 mg/ml = 500 mg
Standard cycle
6–8 weeks

Stanozolol is a DHT-derived synthetic anabolic steroid with a pyrazole ring modification that prevents aromatization and 5α-reductase conversion. The 17α-alkylation present in the molecule allows oral bioavailability but also means that even the injectable form retains some hepatotoxic potential — unlike non-alkylated oil-based injectables, injectable stanozolol is not liver-safe by default. The key practical difference from oral forms is the elimination of gastrointestinal and first-pass hepatic absorption variance: bioavailability is more predictable injection to injection, and the liver receives the compound after systemic circulation rather than directly from the gut portal system.

At 50 mg/day, one 10 ml vial provides 10 doses and covers 10 days of the cycle. A full 8-week cycle at 50 mg/day requires approximately 6 vials. At 50 mg every other day (EOD) — the protocol used by some to reduce injection frequency while maintaining anabolic activity — one vial covers 20 days, and a complete 8-week cycle requires 3 vials. The EOD approach reduces total weekly dose from 350 mg to 175 mg and is the lower-risk protocol for most users.

Stanozolol's SHBG-binding affinity is among the highest of any synthetic AAS. When stacked with testosterone, it releases a meaningful portion of bound testosterone into free circulation, amplifying the effective anabolic output of the base compound without requiring a higher testosterone dose.

What It Does

  • SHBG displacement: Injectable stanozolol binds SHBG with high affinity, freeing circulating testosterone and other androgens from the carrier protein. In a testosterone-based stack, this translates to higher free testosterone levels without increasing exogenous dose.
  • Lean mass retention: Stanozolol preserves nitrogen balance and reduces muscle protein catabolism in a caloric deficit, supporting lean tissue retention through cutting cycles and contest preparation phases.
  • Consistent bioavailability: Administered as an intramuscular injection, injectable stanozolol avoids the dose-to-dose variability in absorption that can affect oral bioavailability. Plasma levels are more stable and predictable across a daily injection schedule.
  • Vascularity and muscle hardness: No estrogenic activity means no water retention and no subcutaneous fluid accumulation. In lean users, injectable stanozolol at 50 mg/day produces pronounced vascular definition and a hardened muscle appearance within the first two weeks.
  • Strength without proportional mass: Like all stanozolol forms, the injectable increases strength disproportionately to body weight added — a reliable characteristic for athletes working within weight categories or seeking performance without scale changes.

Who It's For

Stanabol 50 Inj is the stanozolol format for users already running an injectable cycle who want to add stanozolol without increasing oral compound burden. Adding an aqueous suspension injection alongside an existing injectable AAS is logistically straightforward, and it avoids additional hepatic first-pass load on top of any other orals in the protocol.

The key differentiator from the oral tablets is the reduction in first-pass hepatic exposure — not the elimination of liver risk (the 17α-AA group is present regardless of route), but a meaningfully lower peak concentration reaching the liver directly. For users with mild oral-related liver enzyme elevation who still want stanozolol in the cycle, switching from oral to injectable is the rational protocol adjustment. The injectable also suits users who find oral stanozolol absorption inconsistent or who simply prefer to consolidate all compounds into the injection schedule.

Injectable stanozolol is not for needle-averse users or for those who want the simplicity of a pure oral cycle. Aqueous suspension injections can be more painful at the injection site than oil-based injectables due to the particle suspension characteristics — users new to injectable stanozolol should start with smaller test injections and use a 23–25 gauge needle. Users who need dose flexibility below 50 mg should use Stanabol Tablets 10 mg instead. Users prioritizing liver safety above all else and willing to accept milder results should consider Oxanabol BD.

Stanabol 50 Inj vs Alternatives

Compound Key Differences Choose Stanabol 50 Inj When Choose Alternative When
Stanabol 50 Tabs BD (Stanozolol 50 mg oral) Oral tablet; first-pass hepatic metabolism; GI absorption variance; no injection required; same compound and risk profile Injectable cycle is already running; reducing oral compound burden; more consistent bioavailability needed Oral-only cycle preferred; needle aversion; no injectable experience
Stanabol Tabs BD (Stanozolol 10 mg oral) 10 mg/tab oral; flexible dosing 30–50 mg/day; easy dose titration; first-pass hepatic load; more hepatic risk than injectable Fixed 50 mg/day injectable protocol alongside other injectables; lower hepatic peak concentration preferred Dose below 50 mg/day required; first stanozolol run; oral-only approach
Mastabol 100 BD (Drostanolone propionate) Oil-based injectable; DHT-derived; no 17α-AA — not hepatotoxic; natural anti-estrogenic via androgen:estrogen ratio; less SHBG displacement; density and hardness without liver risk SHBG reduction is the priority; stanozolol's lean mass anti-catabolism is specifically needed Liver health is a constraint; oil-based injectable preferred; natural estrogen management via androgen balance is sufficient
Primobol Inject BD (Methenolone enanthate) Oil-based injectable; no 17α-AA; mild anabolic; no aromatization; not hepatotoxic; lower SHBG effect; weaker but very safe lean mass option Stanozolol's SHBG reduction and harder aesthetic output are priorities; more aggressive lean mass profile required Liver safety is the primary constraint; very mild risk tolerance; longer low-dose runs preferred

Combinations

Goal Primary Support Compounds Notes
Cutting cycle Stanabol 50 Inj 50 mg/day or EOD Testabol Propionate BD Classic injectable cutting combination; Propionate provides testosterone base without excess water; Stanabol 50 Inj adds SHBG reduction and cutting definition; both are short-acting and clear quickly post-cycle
Pre-contest Stanabol 50 Inj 50 mg/day (final 6–8 weeks) Mastabol 100 BD + Testabol Propionate BD All-injectable pre-contest trio; Masteron manages estrogen naturally and adds muscle density; Propionate maintains testosterone baseline; Stanabol 50 Inj drives vascularity, SHBG displacement, and hardness; no oral 17α-AA load in the stack
Lean mass — longer cycle finisher Stanabol 50 Inj 50 mg EOD (final 8 weeks) Testabol Enanthate BD + Anastrozole BD Add Stanabol 50 Inj as a finishing injectable in the last 8 weeks of a longer Enanthate base; Anastrozole controls E2 from Enanthate; Stanabol tightens the physique and raises free testosterone heading into cycle end; EOD dosing reduces total stanozolol load
Lean gains — all injectable Stanabol 50 Inj 50 mg EOD Primobol Inject BD + Testabol Propionate BD Three-injectable lean mass combination; Primo provides mild anabolic base with low androgenic load; Propionate holds testosterone baseline; Stanabol adds SHBG reduction and definition; a lean, dry all-injectable stack with no oral hepatic burden

Side Effects & Management

Side Effect Frequency How to Handle It
Liver toxicity (ALT / AST elevation) Common — lower than oral forms but present due to retained 17α-AA structure Run liver support from day one despite the injectable route: Liv.52 (herbal hepatoprotective, daily), Ursocol / UDCA (300 mg twice daily), and Mucinac / NAC (600–1,200 mg/day); test ALT/AST at baseline and every 4 weeks; stop if >3× upper reference limit
HDL suppression / lipid dysregulation Very common — same systemic lipid impact as oral forms; route of administration does not reduce lipid toxicity Baseline lipid panel mandatory; retest every 4 weeks; cardiovascular support with Ecosprin 75 mg/day throughout; post-cycle statin if HDL does not recover within 4–6 weeks off cycle: Rosulip or Atorlip
Dry joints / arthralgia Common — no water retention reduces synovial fluid cushioning regardless of administration route EOD dosing (vs daily) modestly reduces total weekly dose and may ease joint impact; short-term NSAID: Mobic (meloxicam) for acute joint pain; omega-3 supplementation and collagen support throughout
Injection site discomfort Common — aqueous suspension causes more local irritation than oil-based injectables Warm the vial in the hand before drawing to improve suspension consistency; use 23–25 gauge needle; rotate injection sites (glutes, quads, delts); inject slowly; do not rub injection site vigorously post-injection
Androgenic hair loss Common in genetically predisposed users Topical Minoxidil DP to support follicle longevity; Finasteride DP has limited effectiveness as stanozolol does not convert further via 5α-reductase; switching to Primobol Inject BD is the safest route for hair-sensitive users
Acne Moderate — androgenic DHT-derived stimulation of sebaceous glands Consistent skin hygiene; Doxycycline 100 mg/day for persistent inflammatory acne; isotretinoin only post-cycle and after liver enzymes have cleared
HPTA suppression Moderate — LH and FSH suppressed during the cycle; recovery standard post-PCT Run full PCT immediately after last injection (see PCT section); confirm HPG recovery via LH/FSH and total testosterone bloodwork 4 weeks post-PCT

Bloodwork Monitoring

Lab When to Test Target & Action Threshold
ALT / AST (liver enzymes) Baseline; every 4 weeks on cycle <3× ULN; injectable stanozolol is less hepatotoxic than oral forms but the 17α-AA group still elevates liver enzymes; stop if threshold is exceeded and retest after 2 weeks off
HDL cholesterol Baseline; every 4 weeks >40 mg/dL; injectable route does not reduce stanozolol's lipid toxicity; HDL suppression remains the most critical monitoring marker for this compound
LDL cholesterol Baseline; every 4 weeks <130 mg/dL; stanozolol raises LDL alongside HDL suppression; address post-cycle with a statin if not normalizing
Total cholesterol Baseline; every 4 weeks <200 mg/dL; HDL:LDL ratio more informative than total value alone on any stanozolol protocol
Hematocrit / CBC Baseline; mid-cycle Hematocrit <52%; stanozolol has a mild erythropoietic effect; CBC confirms no unexpected changes across cell lines
LH + FSH Baseline; 4 weeks post-PCT Within normal range post-PCT; confirms full HPG axis recovery following stanozolol-induced suppression
Total testosterone Baseline; post-PCT Return to pre-cycle baseline; recovery of total testosterone at 4 weeks post-PCT confirms successful HPG restoration
Blood pressure Weekly (first month); monthly thereafter <130/80 mmHg; stanozolol does not strongly raise blood pressure independently, but lipid-driven cardiovascular load warrants routine monitoring

PCT

Stanozolol suppresses LH and FSH through HPG axis feedback regardless of administration route. The injectable form has a short active window consistent with its aqueous suspension profile — PCT can begin within 24–48 hours of the final injection, with no extended wait required.

Standard protocol: Clomiphene BD 50 mg/day for weeks 1–2, then 25 mg/day for weeks 3–4; with Tamoxifen BD 20 mg/day throughout all 4 weeks. For users who ran Stanabol 50 Inj as the sole suppressive compound, a standard 4-week SERM protocol is typically sufficient. Confirm LH/FSH and total testosterone recovery via bloodwork at 4 weeks post-PCT completion. If recovery is slow and the cycle included a long-ester testosterone base, adjust PCT timing to account for ester clearance.

Practical Summary

Key Protocol Rules
  • Vial math: 1 vial = 10 days at 50 mg/day; 3 vials cover a full 8-week cycle at 50 mg EOD — EOD dosing is the lower-risk protocol for most users; daily dosing requires 6 vials for an 8-week cycle.
  • Liver support is still mandatory on injectable stanozolol: the 17α-AA molecule is hepatotoxic regardless of route; run Liv.52 + Ursocol (UDCA) + Mucinac (NAC) from day 1; test ALT/AST every 4 weeks.
  • HDL suppression — same lipid risk as oral forms: the injectable route does not reduce stanozolol's systemic lipid impact; Ecosprin 75 mg/day throughout; baseline lipid panel before cycle start.
  • Injection technique for aqueous suspension: warm vial before drawing; shake well; 23–25 gauge needle; rotate injection sites; inject slowly to minimize local discomfort.
  • Dry joints: same mechanism as oral forms — no water retention reduces synovial cushioning; EOD dosing reduces total weekly dose and may ease arthralgia; Mobic short-term for acute episodes.
  • PCT within 48 hours of last injection: Clomiphene BD + Tamoxifen BD for 4 weeks; short active window means no clearance wait is required.

Stanabol 50 Inj British Dragon delivers the full stanozolol pharmacological profile — SHBG reduction, lean mass retention, vascularity, and dry strength gains — in an injectable format that removes oral hepatic first-pass load and GI absorption variability. It is the format of choice for users already on an injectable AAS cycle who want to add stanozolol without increasing oral compound burden. The 17α-AA hepatotoxicity remains a real consideration regardless of route, and liver and lipid monitoring protocols are non-negotiable. For athletes sourcing from Steroid Warehouse who want the cleanest possible stanozolol administration in an all-injectable stack, Stanabol 50 Inj represents the most practical option in the British Dragon stanozolol lineup.

References

Source Topic Link
New England Journal of Medicine / PubMed Bhasin et al. 1996 — randomized controlled trial evaluating 600 mg/week testosterone enanthate in healthy men with and without resistance training; demonstrated significant increases in fat-free mass, muscle size, and strength, establishing the anabolic effects of supraphysiologic testosterone administration Bhasin S, et al. (1996) ↗
NCBI Bookshelf / StatPearls Anabolic steroids overview — clinical reference on synthetic testosterone-derived anabolic-androgenic steroids, androgen receptor activity, oral and injectable forms, adverse effect profiles, misuse patterns, and monitoring considerations StatPearls: Anabolic Steroids ↗
NCBI Bookshelf / Endotext Androgen physiology and pharmacology — comprehensive overview of testosterone, dihydrotestosterone, androgen receptor signaling, HPG-axis regulation, synthetic androgen pharmacology, aromatization, and endocrine suppression associated with exogenous androgen use Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗
JAMA / PubMed Thompson PD et al. 1989 — study comparing the effects of testosterone and stanozolol on serum lipoprotein levels; reported increased LDL cholesterol and marked HDL suppression with stanozolol, supporting its unfavorable lipid-profile effects Thompson PD, et al. (1989) ↗
Sports Medicine / PubMed Hartgens F & Kuipers H 2004 — review of androgenic-anabolic steroid effects in athletes; covers body composition, strength, lipid profiles, cardiovascular effects, endocrine suppression, hepatic effects, and psychological considerations across multiple anabolic-androgenic steroids Hartgens F & Kuipers H (2004) ↗
What is Stanabol 50 Inj?

Stanabol 50 Inj is an injectable anabolic steroid (Stanozolol) for lean muscle and definition; see What is Stanabol 50 Inj. It's potent—consult professionals for safe use.

What does Stanabol do?

It promotes lean muscle, strength, and fat loss; see What Does Stanabol Do. It enhances definition—monitor with labs.

How often to inject Stanabol 50 Inj?

Inject every other day or thrice weekly (e.g., 50-100 mg); see How Often to Inject Stanabol 50 Inj. Consult professionals for protocols.

What size syringe for Stanabol 50 injection?

Use a 3 ml syringe with 22-25 gauge needle for IM; see What Size Syringe for Stanabol 50 Injection. Use sterile equipment—consult professionals.

How do I take Stanabol?

50-100 mg EOD for men, 10-25 mg EOD for women; see How to Take Stanabol. Start low—consult professionals for dosing.

How does Stanabol 50 Inj work?

Users often report gradual improvements in strength, muscle hardness, vascularity, and overall physique appearance within several weeks of consistent use.

What are the main benefits of Stanabol 50 Inj?

Commonly reported benefits include enhanced muscle definition, increased strength, improved vascularity, support for lean muscle retention, and a dry, aesthetic physique appearance.

What makes Stanabol 50 Inj different from oral stanozolol products?

Stanabol 50 Inj delivers stanozolol through injection rather than oral administration while maintaining the muscle-hardening and physique-enhancing characteristics associated with the compound.